The differences in clinical features and prognosis between hypoplastic myelodysplastic syndrome (h-MDS) and normo-/hypercellular MDS (NH-MDS) remain unsettled. In this study, the characteristics of 37 h-MDS patients and 152 NH-MDS patients were compared. Peripheral-blood white blood cell counts and bone marrow blast percentage were lower in h-MDS patients than in NH-MDS patients (P=0.012 and 0.016, respectively). Refractory anemia (RA) was predominant (56.8%) in h-MDS, whereas RA with excess of blast (RAEB) was most common (44.7%) in NH-MDS. Chromosomal abnormalities -7/7q- occurred less frequently in h-MDS patients than in NH-MDS patients (0 vs 18.3%, P=0.022). There was no significant difference in the prevalence of mutations of RAS, AML1, JAK2, PTPN11, FLT3/ITD, and hypermethylation of SOCS1 and SHP1 between these two groups. International Prognostic Scoring System (IPSS) was ideal for predicting prognoses in h-MDS patients (P=0.002). In low- or intermediate-1 (Int-1)-risk MDS patients, h-MDS patients had a superior survival than NH-MDS patients (P=0.01). In conclusion, distinct from NH-MDS, h-MDS patients have different patterns of hemogram, distribution of French-American-British subtypes, cytogenetic changes and prognoses. IPSS is applicable in h-MDS as in NH-MDS. In patients with low- or Int-1-risk MDS, h-MDS patients have a better prognosis than NH-MDS patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/sj.leu.2405076 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Article Synopsis
- The Molecular International Prognostic Scoring System (IPSS-M) is a new model for assessing risk in patients with myelodysplastic syndromes (MDS) that incorporates genetic mutation data for better accuracy compared to previous systems like IPSS and IPSS-R.
- A large study involving 2,355 MDS patients confirmed the IPSS-M's effectiveness in predicting overall survival (OS), leukemia-free survival (LFS), and the risk of leukemic transformation.
- The model categorizes patients into six risk groups, showing significant differences in median survival times, which supports the potential of IPSS-M to enhance treatment decisions for MDS patients.
Circulating HMGB1 is increased in myelodysplastic syndrome but not in other bone marrow failure syndromes: proof-of-concept cross-sectional study.
Ther Adv Hematol
October 2022
Departmento de Infectología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Article Synopsis
- Myelodysplastic syndrome (MDS) is linked with ongoing immune activation, and the study investigates the role of the protein high mobility group box-1 (HMGB1) in patients with MDS and other bone marrow failure syndromes like aplastic anemia (AA) and paroxysmal nocturnal hemoglobinuria (PNH).
- The research involved measuring levels of HMGB1 and other inflammatory markers in MDS patients, healthy controls, and those with AA and PNH, finding significantly higher HMGB1 levels in MDS patients compared to others.
- A specific HMGB1 level (4.095 ng/ml) was identified as a potential marker to differentiate between hypocellular MDS and AA, suggesting a
Immunoexpression of CD34, CD117, and p53 in Hypocellular Bone Marrow Disorders.
J Lab Physicians
June 2022
Department of Medicine, Government Medical College and Hospital, Chandigarh, India.
Article Synopsis
- The study focuses on hypocellular bone marrow disorders, which lead to low blood cell production and result in conditions like aplastic anemia (AA), hypocellular myelodysplastic syndrome (h-MDS), and hypocellular acute myeloid leukemia (h-AML).
- Researchers analyzed bone marrow samples from 30 patients with low cellularity (<30%) and used immunohistochemistry to assess the expression levels of CD34, CD117, and p53 proteins, finding significant differences between h-MDS/h-AML and AA.
- The study concluded that CD34 and p53 are useful for distinguishing between hypocellular bone marrow disorders, while the significance of CD117 is uncertain and requires more extensive
Plasma lipidome acts as diagnostic marker and predictor for cyclosporin response in patients with aplastic anemia.
Clin Exp Med
July 2023
Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, 100730, China.
The lipid metabolomic profile has been well defined in the pathogenesis and differential diagnosis in patients with different myeloid diseases. We assumed that the serum lipid metabolites could also help the diagnosis and prognostic prediction of aplastic anemia (AA). In this study, serum lipid profiles were explored in AA patients before and after cyclosporin (CsA) treatment.
View Article and Find Full Text PDFThe utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm.
Int J Lab Hematol
December 2021
Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.
Introduction: The diagnosis of myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) is based on morphology and cytogenetics/FISH findings per 2017 WHO classification. With rare exceptions, somatic mutations have not been incorporated as the diagnostic criteria.
Methods: We analyzed the utility of mutational analysis with a targeted 54-gene or 40-gene next-generation sequencing (NGS) panel in the diagnosis of MDS and MDS/MPN.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!